PLPIPost - September 2024
In this issue
Pharmacovigilance (PV) for PLPI licences – a reminder
Wholesalers & manufacturers guidance following agreement of the Windsor Framework
PLPI Information Update
Contacting assessors/ RIS / Customer services - a reminder
Admin team zone
Monthly statistics
Pharmacovigilance (PV) for PLPI licences – a reminder
As part of the PLPI licence grant conditions, when the cross-reference UK licence has been cancelled for non-safety related reasons (rather than undergoing a change of ownership), the PI licence holder is required to take on responsibility for pharmacovigilance of the imported product to continue marketing the product in the UK.
A transition period of 6 months will be allowed for companies to consider whether to cancel their licence or put in place PV requirements.
PV requirements comprise of two main aspects:
1. Management of ADR reports
The PLPI holder must:
- Collate and maintain records relating to suspected adverse drug reactions (ADRs) reported to them.
- Make the above records available for inspection as required.
- Report serious ADRs to the MHRA.
In addition to the above, all ADRs reported to the PI holder must also be reported to the MHRA via the Yellow Card scheme.
Further information on submitting ADRs can be found on the MHRA website and the Yellow Card reporting site.
2. Maintenance of the patient information
The PI licence holder must ensure that the leaflet included in the medicine pack contains up to date information on the safe and effective use of the medicine. Initially, the PI leaflet should comply with the latest revision of the cross-referred UK product leaflet. The PI licence holder must then carry out monthly checks to monitor all appropriate information sources (e.g. PRAC recommendations, safety referrals, PSURs, CMDh agendas and minutes etc.) and update the leaflet, as necessary.
Records of monitoring activity must be maintained and updates to labels may also be required.
Additional measures may be required for some products, for example additional risk minimisation measures (aRMMs) and Periodic Safety Update Reports (PSURs). The need for these will be determined on a case-by-case basis.
PI licence holders must develop their own internal processes and procedures to fulfil these responsibilities and you must also ensure that suitably qualified PV and regulatory staff are available to operate the processes.
The effectiveness of the PV systems will be checked during inspections and may be the subject of a separate PV inspection visit.
For further information on PV requirements, please refer to the PLPI Posts dated February 2020 and February 2021.
We may occasionally include a current list of cancelled UK cross-reference licences, however the responsibility for checking the status of the UK cross-reference licence is with the PI licence holder. These checks should be part of your monthly licence checks.
Below is a current list of cancelled UK cross-reference licences. Please ensure that if any of your PI licences are cross-referred to any of these cancelled UK licences that you undertake additional PV responsibilities or you cancel your licence.
|
Product Name
|
UK PL/PLGB No
|
Active
|
Cancellation date
|
|
Actonel 5mg Film-coated Tablets
|
PL 20075/1067
|
risedronate sodium
|
18/11/2022
|
|
Actos 15 mg tablets
|
PLGB 45043/0086
|
pioglitazone hydrochloride
|
11/01/2023
|
|
Actos 30 mg tablets
|
PLGB 45043/0087
|
pioglitazone hydrochloride
|
11/01/2023
|
|
Actos 45 mg tablets
|
PLGB 45043/0088
|
pioglitazone hydrochloride
|
11/01/2023
|
|
Acupan Tablets
|
PL 46302/0091
|
nefopam hydrochloride
|
20/04/2022
|
|
Adalat LA 60mg tablets
|
PL 00010/0175
|
nifedipine
|
26/11/2020
|
|
Adalat Retard 20mg tablets
|
PL 00010/0078
|
nifedipine
|
01/10/2019
|
|
Anafranil 75mg
|
PL 00101/0436
|
clomipramine hydrochloride
|
24/07/2018
|
|
Antepsin 1g/5ml oral suspension
|
PL 12185/0010
|
sucralfate
|
20/09/2019
|
|
Aprovel 75mg Tablets
|
PLGB 04425/0790
|
irbesartan
|
11/05/2021
|
|
Artelac 0.32% w/v eye drops single dose unit
|
PL 03468/0033
|
hypromellose
|
23/07/2024
|
|
Bromocriptine 2.5 mg Tablets
|
PL 00289/1395
|
bromocriptine mesylate
|
09/12/2019
|
|
Celectol 400 Tablets
|
PL 45043/0028
|
celiprolol hydrochloride
|
13/10/2023
|
|
CoAprovel 300mg/25mg film-coated Tablets
|
PLGB 04425/0793
|
irbesartan, hydrochlorothiazide
|
09/08/2023
|
|
Co-danthramer 25mg/200mg per 5ml oral suspension
|
PL 04917/0025
|
dantron, poloxamer 188
|
29/05/2024
|
|
Danol 200mg Capsules
|
PL 04425/0195
|
danazol
|
02/12/2022
|
|
Desmopressin Teva 0.1mg tabs
|
PL 00289/1010
|
desmopressin
|
28/12/2017
|
|
Detrunorm 15mg Coated Tablets
|
PL 20072/0015
|
propiverine hydrochloride
|
25/03/2022
|
|
Flagyl S 200mg/5ml oral suspension
|
PL 04425/0747
|
metronidazole benzoate
|
18/01/2022
|
|
Flixotide 0.5mg/2ml Nebules
|
PL 10949/0297
|
fluticasone propionate
|
07/05/2024
|
|
Flixotide 2mg/2ml Nebules
|
PL 10949/0298
|
fluticasone propionate
|
06/12/2023
|
|
Foradil 12mcg Capsules
|
Pl 00101/0464
|
formoterol fumarate
|
18/03/2023
|
|
Frumil LS 20 mg/2.5 mg Tablets
|
PL 04425/0574
|
furosemide, amiloride hydrochloride
|
08/01/2023
|
|
Haldol 10mg
|
PL 00242/0039R
|
haloperidol
|
20/10/2016
|
|
Haldol 5mg
|
PL 00242/0031R
|
haloperidol
|
20/10/2016
|
|
Haldol injection
|
PL 00242/0036R
|
haloperidol
|
21/05/2018
|
|
Hygroton 50mg Tablets
|
PL 16853/0007
|
chlortalidone
|
22/04/2020
|
|
Hygroton 50mg Tablets
|
PL 42757/0006
|
chlortalidone
|
26/05/2020
|
|
Hypovase 1mg Tablets
|
PL 00057/0106R
|
prazosin hydrochloride
|
23/06/2023
|
|
Jevtana 60mg concentrate and solvent for solution for infusion
|
PLGB 04425/0825
|
cabazitaxel
|
04/08/2023
|
|
Lescol XL 80mg Prolonged Release Tablets
|
PL 23860/0015
|
fluvastatin sodium
|
20/02/2023
|
|
Levitra 20mg film-coated Tablets
|
PLGB 00010/0699
|
vardenafil hydrochloride trihydrate
|
26/06/2023
|
|
Lyrinel XL 5mg prolonged-release tablets
|
PL 00242/0385
|
oxybutynin hydrochloride
|
15/09/2022
|
|
Lyxumia 20 mcg solution for injection
|
PLGB 04425/0832
|
lixisenatide
|
03/01/2024
|
|
Megace 160mg Tablets
|
PL 03468/0089
|
megestrol acetate
|
15/01/2024
|
|
Metoject 50 mg/ml solution for injection
|
PL 11587/0046
|
methotrexate
|
21/06/2021
|
|
Nalacrom 100mg Capsules
|
PL 04425/0370
|
sodium cromoglicate
|
20/06/2023
|
|
Ofloxacin Teva 400mg tablets
|
PL 14776/0055
|
ofloxacin
|
02/12/2019
|
|
Rasilez 150 mg film-coated tablets
|
PLGB 48724/0001
|
aliskiren hemifumarate
|
01/08/2024
|
|
Rasilez 300 mg film-coated tablets
|
PLGB 48724/0002
|
aliskiren hemifumarate
|
01/08/2024
|
|
Restandol Testocaps 40mg capsules
|
PL 00025/0595
|
testosterone undecanote
|
06/01/2021
|
|
Rhinocort Aqua 64 micrograms Nasal Spray
|
PL 15513/0403
|
budesonide
|
28/06/2021
|
|
Rinatec 21 micrograms per metered dose, Nasal Spray Solution
|
PL 53886/0059
|
ipratropium bromide
|
10/05/2024
|
|
Risperdal 0.5mg Tablets
|
PL 00242/0347
|
risperidone
|
19/01/2024
|
|
Risperdal 1mg Tablets
|
PL 00242/0186
|
risperidone
|
19/01/2024
|
|
Risperdal 1mg/ml oral solution
|
PL 00242/0199
|
risperidone
|
19/01/2024
|
|
Risperdal 2mg Tablets
|
PL 00242/0187
|
risperidone
|
19/01/2024
|
|
Risperdal 3mg Tablets
|
PL 00242/0188
|
risperidone
|
19/01/2024
|
|
Rivotril 0.5mg
|
PL 00031/0076R
|
clonazepam
|
31/08/2014
|
|
Rivotril 2mg
|
PL 00031/0077R
|
clonazepam
|
31/08/2014
|
|
Rizatriptan 10mg orodispersible tablets
|
PL 04569/1149
|
rizatriptan
|
29/12/2023
|
|
Sectral 400mg Tablets
|
PL 45043/0061
|
acebutolol
|
09/03/2023
|
|
Seroxat 20mg/10ml Oral Suspension
|
PL 10592/0092
|
paroxetine
|
01/07/2024
|
|
Tesavel 50mg film-coated tablets
|
PLGB 53095/0076
|
sitagliptin phosphate monohydrate
|
20/12/2023
|
|
Transiderm-Nitro 5
|
PL 00101/0464
|
nitroglycerin
|
13/10/2023
|
|
Transiderm-Nitro10
|
PL 00101/0465
|
nitroglycerin
|
13/10/2023
|
|
Triapin 5mg/5mg prolonged release tablets
|
PL 04425/0320
|
felodipine, ramipril
|
21/03/2022
|
|
Voltarol SR 75mg
|
PL 00101/0471
|
diclofenac sodium
|
11/12/2017
|
|
Xelevia 100mg film-coated tablets
|
PLGB 53095/0079
|
sitagliptin phosphate monohydrate
|
20/12/2023
|
|
Xelevia 25mg film-coated tablets
|
PLGB 53095/0080
|
sitagliptin phosphate monohydrate
|
20/12/2023
|
|
Xelevia 50mg film-coated tablets
|
PLGB 53095/0081
|
sitagliptin phosphate monohydrate
|
20/12/2023
|
|
Xtandi 40mg Capsules
|
PLGB 00166/0422
|
enzalutamide
|
10/04/2024
|
|
Zarontin 250mg/5ml Syrup
|
PL 41871/0016
|
ethosuximide
|
11/05/2017
|
|
Zofran Melt 4mg
|
PL 00101/0983
|
ondansetron hydrochloride
|
11/07/2023
|
|
Zofran Melt 8mg
|
PL 00101/0984
|
ondansetron hydrochloride
|
11/07/2023
|
|
Zyprexa 10mg Injection
|
PLGB 14895/0289
|
olanzapine
|
23/01/2024
|
Wholesalers & manufacturers guidance following agreement of the Windsor Framework
A new Windsor framework guidance has been published for wholesalers and manufacturers. This guidance is designed to support manufacturers and wholesale dealers authorised by the Medicines and Healthcare products Regulatory Agency (MHRA) and the associated Qualified Persons (QPs), Responsible Persons (RPs) and Responsible Persons for Import (RPis) in order to implement the arrangements of the Windsor Framework for human medicines.
Contacting assessors/ RIS / Customer services – a reminder
Assessors are busy working on your applications and should be contacted only if absolutely necessary.
If you wish to find out the status of your application (initials and/or variations) or you are requesting approved documentation for your granted licence such as grant letters, labelling documents or leaflets or any other enquiry relating to product licences and any other regulatory activity, please contact RIS by e-mail: RIS.NA@mhra.gov.uk or by telephone on 020 3080 7400.
To obtain the current Patient Information Leaflet (PIL) or Summary of Product Characteristics (SmPC) document, please search MHRA Products website.
For all other general enquiries, contact Customer Services by email: info@mhra.gov.uk or call 020 3080 6000.
Admin team zone
The PLPI Admin team is responsible for all administrative work for a licence - post submission validation and post application assessment. This consists of processing submitted samples, requesting product information from EU regulatory bodies, and preparing grant documentations.
For any admin related queries, please email plpi.admin@mhra.gov.uk
Monthly statistics
Every month a series of reports from the Sentinel database are run to monitor various aspects of Parallel Import Licence granting performance. Each month we will include the current statistics for some key parameters in The PLPI Post so that you can see how we are doing. Please let us know if there is something you would like included.
|
Measure
|
July 2024
|
August 2024
|
September 2024
|
|
Initial Parallel Import Applications received
|
104 |
55 |
53 |
|
Initial Parallel Import Licences granted
|
85 |
72 |
120 |
|
Initial Parallel Import Applications determined
|
86 |
75 |
123 |
|
Minimum time to grant (months)
|
1.4 |
7.2 |
1.8 |
|
Median time to grant (months)
|
10.4 |
10.8 |
10.8 |
|
Time to start assessment (months)
|
10.7 |
9.7 |
9.3 |
| |
|
|
|
|
Variations received
|
489 |
1169 |
440 |
|
Variations granted
|
1182 |
1489 |
1552 |
|
Time to grant leaflets (months)
|
4.2 |
3.0 |
3.6 |
|
Time to grant pharmaceutical (months)
|
4.0 |
4.5 |
3.4 |
|
Time to grant admin (months)
|
1.4 |
1.6 |
0.3 |
For any PLPI related queries contact: RIS.NA@mhra.gov.uk
Contact address: PLPI Unit / Healthcare Quality and Access, MHRA, 10 South Colonnade, Canary Wharf, London, E14 4PU
If you wish to unsubscribe to these emails, please reply to RIS.NA@mhra.gov.uk with ‘Unsubscribe’ in the subject line.
View and download the full PDF newsletter
|